A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 179, 112949
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Sunitinib: the antiangiogenic effects and beyondOncoTargets and Therapy, 2016
- Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MSClinica Chimica Acta, 2011
- Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometryJournal of Chromatography B, 2010
- Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2010
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemotherapy and Pharmacology, 2009
- A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasmaJournal of Chromatography B, 2009
- Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometryJournal of Chromatography B, 2009
- Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasmaClinica Chimica Acta, 2009
- Quantification of sunitinib in human plasma by high-performance liquid chromatography–tandem mass spectrometry☆Journal of Chromatography B, 2008
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006